top of page

Protecting Patients with NERLYNX the only HER2-directed small molecule approved by the FDA ~ Oct 7th

PLEASE REGISTER ONLINE AT: PUMAREG.TSGMEDED.COM Enter Event Code:51684




This program is sponsored by Puma Biotechnology, Inc. This is not an independent educational program, and no CME credits will be provided.

ADVERSE REACTIONS: The most common adverse reactions (reported in ≥ 5% of patients) were:

  • NERLYNX as a single agent: diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, AST or ALT increased, nail disorder, dry skin, abdominal distention, epistaxis, weight decreased, and urinary tract infection.

  • NERLYNX in combination with capecitabine: diarrhea, nausea, vomiting, decreased appetite, constipation, fatigue/asthenia, weight decreased, dizziness, back pain, arthralgia, urinary tract infection, upper respiratory tract infection, abdominal distention, renal impairment, and muscle spasms.


51684 Invitation 10.7
.pdf
Download PDF • 407KB

9 views0 comments

Recent Posts

See All

Cancer Equity Colloquium 2024

Now more than ever, the presence of social inequities in healthcare is evident. This two-day, hybrid event, the Cancer Equity Colloquium, will address the diverse issues that underlie cancer inequitie

Comentários


bottom of page